ABIONYX Pharma announced that following the Board of Directors meeting held on 6 September 2019, Cyrille TUPIN, Deputy CEO of the company since December 2018, was appointed CEO. Cyrille Tupin succeeds Richard Pasternak, and Mr. Tupin becomes a director of the company, replacing Michael H. Davidson who is resigning as a director.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.25 EUR | +5.93% | +2.80% | -2.95% |
14/03 | Abionyx Pharma: to benefit from a 1ME grant from Bpifrance | CF |
11/03 | Abionyx: reduced net loss in 2023 | CF |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-2.95% | 4.12Cr | |
+11.91% | 11TCr | |
+11.60% | 10TCr | |
-4.68% | 2.38TCr | |
-0.82% | 2.17TCr | |
-10.12% | 1.81TCr | |
-42.12% | 1.63TCr | |
-17.47% | 1.61TCr | |
+2.77% | 1.38TCr | |
+34.58% | 1.18TCr |
- Stock Market
- Equities
- ABNX Stock
- News ABIONYX Pharma
- ABIONYX Pharma SA Announces Executive Changes